Latest Precision Medicine News

PYC Therapeutics has completed dosing in its Phase 1 study of PYC-001 for Autosomal Dominant Optic Atrophy, showing strong safety and early signs of improved vision. The company plans to launch a global Phase 1/2 trial later this year.

PYC Therapeutics has reported promising safety data from the initial phase of its clinical trial for PYC-003, an RNA therapy targeting the root cause of Polycystic Kidney Disease. The findings, presented at the ANZSN conference, highlight the drug’s tolerability in healthy volunteers, paving the way for further clinical development.

PYC Therapeutics reported a 14.5% rise in income to AUD 26.17 million for FY2025 alongside a 33.3% increase in net loss, while increasing its stake in Vision Pharma to 97.1%. The auditor flagged material uncertainty over the company’s ability to continue as a going concern.

Rhythm Biosciences has formalised a strategic co-marketing partnership with the Know Your Lemons Foundation to promote its geneType Breast Cancer Risk Assessment Test, expanding access to early detection tools for women in the US and Australia.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.

PYC Therapeutics has escalated dosing to the highest level in its Phase 1a trial of PYC-003 and begun dosing patients with Polycystic Kidney Disease, marking key progress toward regulatory milestones.

Rhythm Biosciences has responded to an ASX price query following a sudden surge in its share price and trading volume, confirming no undisclosed information is driving the activity.

Proteomics International Laboratories has secured $12 million to fast-track its precision diagnostic tests, including the US launch of PromarkerD for diabetic kidney disease, backed by a new AMA billing code. The company also advances its pipeline with new patents and commercial partnerships.

Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.

Telix Pharmaceuticals has achieved a key milestone with its next-generation prostate cancer imaging agent, Gozellix, receiving a permanent HCPCS code from U.S. Medicare. This paves the way for broader reimbursement and market adoption starting October 2025.